Tarsus Pharmaceuticals (TARS) CEO Bobak Azamian Sells 10,000 Shares

What Happened
Bobak Azamian, President & CEO and Chair of the Board of Tarsus Pharmaceuticals (TARS), reported the sale of 10,000 shares on 2026-09-02. The shares were disposed of in an open-market sale at a weighted average price of $80.06 per share, for total gross proceeds of approximately $800,600. This was a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date: 2026-09-02; Form 4 filed: 2026-09-03 (timely filing).
• Transaction type: Sale (Code S).
• Shares sold: 10,000 at a weighted average price of $80.06; reported price range $80.00–$80.20.
• Total proceeds: ≈ $800,600.
• Footnotes: sale was executed automatically under a Rule 10b5-1 trading plan adopted December 9, 2025; the reporting person is trustee of the Bobak Azamian Living Trust (voting and dispositive power). The filer notes they can provide a breakdown of the number of shares sold at each price within the stated range upon request.
• Shares owned after transaction: Not specified in the summary provided.

Context
Because the sale was made under a pre-established 10b5-1 plan, it reflects a pre-planned disposition rather than an opportunistic trade; such sales are often routine and do not necessarily indicate a change in the insider’s view of the company. No option exercises, gifts, or tax-withholding actions are indicated in this filing.